about us
BioVax TB Research Group
The BioVax TB Research Group (TRG) at Universitas Hasanuddin is a research-driven initiative dedicated to advancing scientific solutions for Tuberculosis (TB) through innovation in molecular science, genomics, and biotechnology.
Operating within a high TB-burden setting, the group is uniquely positioned to address real-world challenges in TB control. BioVax TB TRG integrates laboratory research, clinical insight, and genomic technologies to generate impactful and translational outcomes.
Our work focuses on bridging the gap between discovery and application transforming scientific findings into practical solutions for improved diagnostics, treatment strategies, and vaccine development.
our approach
- Integration of genomics, biotechnology, and clinical research
- Strong emphasis on translational research (bench-to-bedside)
- Multidisciplinary and collaborative research environment
- Alignment with national and global TB research priorities
how we works
Our Working Proccess
Research Focus
Our research focuses on addressing critical challenges in tuberculosis through integrated approaches spanning molecular science, genomics, and translational research.
Molecular Diagnostics
Advancing rapid and accurate detection of TB using molecular and genomic technologies
Drug-Resistant TB
Investigating resistance mechanisms to improve diagnostic precision and treatment strategies
Vaccine Research & Development
Exploring antigen-based approaches toward next-generation TB vaccines
Genomics & Biomarkers
Understanding host–pathogen interactions to support targeted interventions
BioVax TB TRG
BioVax TB TRG offers a research environment that is both scientifically rigorous and globally relevant:
- Located in a high TB-burden setting, enabling impactful and context-driven research
- Focused on real-world application of scientific discovery
- Growing capacity in genomics and biotechnology research
- Open to collaboration and interdisciplinary engagement
We welcome researchers, collaborators, and partners to join us in advancing tuberculosis research and innovation.
